Strategies for meloxicam delivery to and across the skin: a review

References

• Abdul Rasool KB, Gareeb RH, Fahmy SA, et al. (2011). Meloxicam β-cyclodextrin transdermal gel: physicochemical characterization and in vitro dissolution and diffusion studies. Curr Drug Deliv 8:381–91
   PubMed Web of Science ®Google Scholar
• Ah YC, Choi JK, Choi YK, et al. (2010). A novel transdermal patch incorporating meloxicam: in vitro and in vivo characterization. Int J Pharm 385:12–19
   PubMed Web of Science ®Google Scholar
• Ahad A, Raish M, Al-Mohizea AM, et al. (2014). Enhanced anti-inflammatory activity of carbopol loaded meloxicam nanoethosomes gel. Int J Biol Macromol 67:99–104
   PubMed Web of Science ®Google Scholar
• Altman RD, Barthel HR. (2011). Topical therapies for osteoarthritis. Drugs 71:1259–79
   PubMed Web of Science ®Google Scholar
• Arantes-Rodrigues R, Pinto-Leite R, Ferreira R, et al. (2013). Meloxicam in the treatment of in vitro and in vivo models of urinary bladder cancer. Biomed Pharmacother 67:277–84
   PubMed Web of Science ®Google Scholar
• Bachhav YG, Patravale VB. (2010). Formulation of meloxicam gel for topical application: in vitro and in vivo evaluation. Acta Pharm 60:153–63
   PubMed Web of Science ®Google Scholar
• Badran MM, Taha EI, Tayel MM, et al. (2014). Ultra-fine self nanoemulsifying drug delivery system for transdermal delivery of meloxicam: dependency on the type of surfactants. J Mol Liq 190:16–22
   Web of Science ®Google Scholar
• Barhate SD. (2011). Development of meloxicam sodium transdermal gel. Int J Pharm Res Dev 2:1–4
   Google Scholar
• Busch U, Schmid J, Heinzel G, et al. (1998). Pharmacokinetics of meloxicam in animals and the relevance to humans. Drug Metab Dispos 26:576–84
   PubMed Web of Science ®Google Scholar
• Cevc G, Blume G. (1992). Lipid vesicles penetrate into intact skin owing to the transdermal osmotic gradients and hydration force. Biochim Biophys Acta 1104:226–32
   PubMed Web of Science ®Google Scholar
• Cevc G, Richardsen H. (1999). Lipid vesicles and membrane fusion. Adv Drug Deliv Rev 38:207–32
   PubMed Web of Science ®Google Scholar
• Chang J-S, Huang Y-B, Hou S-S, et al. (2007a). Formulation optimization of meloxicam sodium gel using response surface methodology. Int J Pharm 338:48–54
   PubMed Web of Science ®Google Scholar
• Chang J, Wu P, Huang Y, et al. (2006). In-vitro evaluation of meloxicam permeation using response surface methodology. J Food Drug Anal 14:236--41
   Web of Science ®Google Scholar
• Chang JS, Tsai YH, Wu PC, et al. (2007b). The effect of mixed-solvent and terpenes on percutaneous absorption of meloxicam gel. Drug Dev Ind Pharm 33:984–9
   PubMed Web of Science ®Google Scholar
• Conditions NCCfC. Osteoarthritis: national clinical guideline for care and management in adults. 2008. London (UK): Royal College of Physicians
   Google Scholar
• Cui L, Hou X, Jiang J, et al. (2008). Comparative enhancing effects of electret with chemical enhancers on transdermal delivery of meloxicam in vitro. J Phys Conf Ser 142:1–4
   Google Scholar
• Davies NM, Skjodt NM. (1999). Clinical pharmacokinetics of meloxicam. A cyclo-oxygenase-2 preferential nonsteroidal anti-inflammatory drug. Clin Pharmacokinet 36:115–26
   PubMed Web of Science ®Google Scholar
• Deeks JJ, Smith LA, Bradley MD. (2002). Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ 325:619
   PubMed Web of Science ®Google Scholar
• Degner F, Sigmund R, Zeidler H. (2000). Efficacy and tolerability of meloxicam in an observational, controlled cohort study in patients with rheumatic disease. Clin Ther 22:400–10
   PubMed Web of Science ®Google Scholar
• Distel M, Mueller C, Bluhmki E, et al. (1996). Safety of meloxicam: a global analysis of clinical trials. Br J Rheumatol 35:68–77
   PubMedGoogle Scholar
• Dong X, Ke X, Liao Z. (2011). The microstructure characterization of meloxicam microemulsion and its influence on the solubilization capacity. Drug Dev Ind Pharm 37:894–900
   PubMed Web of Science ®Google Scholar
• Duan X-D, Ji C-J, Nie L. (2015). Formulation and development of dendrimer-based transdermal patches of meloxicam for the management of arthritis. Trop J Pharm Res 14:583–90
   Web of Science ®Google Scholar
• Duangjit S, Obata Y, Sano H, et al. (2012). Menthosomes, novel ultradeformable vesicles for transdermal drug delivery: optimization and characterization. Biol Pharm Bull 35:1720–8
   PubMed Web of Science ®Google Scholar
• Duangjit S, Obata Y, Sano H, et al. (2014a). Comparative study of novel ultradeformable liposomes: menthosomes, transfersomes and liposomes for enhancing skin permeation of meloxicam. Biol Pharm Bull 37:239–47
   PubMed Web of Science ®Google Scholar
• Duangjit S, Opanasopit P, Rojanarata T, et al. (2010). Characterization and in vitro skin permeation of meloxicam-loaded liposomes versus transfersomes. J Drug Deliv 2011:1–9
   Google Scholar
• Duangjit S, Opanasopit P, Rojanarata T, et al. (2013). Evaluation of meloxicam-loaded cationic transfersomes as transdermal drug delivery carriers. AAPS PharmSciTech 14:133–40
   PubMed Web of Science ®Google Scholar
• Duangjit S, Pamornpathomkul B, Opanasopit P, et al. (2014b). Role of the charge, carbon chain length, and content of surfactant on the skin penetration of meloxicam-loaded liposomes. Int J Nanomedicine 9:2005–17
   PubMed Web of Science ®Google Scholar
• El-Badry M, Fathy M. (2006). Enhancement of the dissolution and permeation rates of meloxicam by formation of its freeze-dried solid dispersions in polyvinylpyrrolidone K-30. Drug Dev Ind Pharm 32:141–50
   PubMed Web of Science ®Google Scholar
• El-Badry M, Fetih G, Fathalla D, et al. (2014). Transdermal delivery of meloxicam using niosomal hydrogels: in vitro and pharmacodynamic evaluation. Pharm Dev Technol 20:820–6
   PubMed Web of Science ®Google Scholar
• El-Menshawe SF, Hussein AK. (2013). Formulation and evaluation of meloxicam niosomes as vesicular carriers for enhanced skin delivery. Pharm Dev Technol 18:779–86
   PubMed Web of Science ®Google Scholar
• Elmotasem H. (2008). Chitosan–alginate blend films for the transdermal delivery of meloxicam. Asian J Pharm Sci 3:12–29
   Google Scholar
• Elsayed MM, Abdallah OY, Naggar VF, et al. (2006). Deformable liposomes and ethosomes: mechanism of enhanced skin delivery. Int J Pharm 322:60–6
   PubMed Web of Science ®Google Scholar
• Fenn GC, Morant SV. (1997). Safety of meloxicam: a global analysis of clinical trials [British Journal of Rheumatology, 1996;35(suppl. 1):68-77]. Br J Rheumatol 36:817–19
   PubMedGoogle Scholar
• Fetih G. (2010). Meloxicam formulations for transdermal delivery: hydrogels versus organogels. J Drug Deliv Sci Technol 20:451–6
   Web of Science ®Google Scholar
• Gao QZ, Yang LY, Ding PT, et al. (2007). [Percutaneous absorption of meloxicam patches in hairless mouse]. Yao Xue Xue Bao 42:1320–2
   PubMedGoogle Scholar
• Goldman AP, Williams CS, Sheng H, et al. (1998). Meloxicam inhibits the growth of colorectal cancer cells. Carcinogenesis 19:2195–9
   PubMed Web of Science ®Google Scholar
• Gupta SK, Bansal P, Bhardwaj RK, et al. (2002). Comparison of analgesic and anti-inflammatory activity of meloxicam gel with diclofenac and piroxicam gels in animal models: pharmacokinetic parameters after topical application. Skin Pharmacol Appl Skin Physiol 15:105–11
   PubMedGoogle Scholar
• Hatanaka T, Kamon T, Morigaki S, et al. (2000). Ion pair skin transport of a zwitterionic drug, cephalexin. J Control Release 66:63–71
   PubMed Web of Science ®Google Scholar
• Hoffman AS. (2012). Hydrogels for biomedical applications. Adv Drug Del Rev 64:18–23
   Web of Science ®Google Scholar
• Huang CT, Tsai CH, Tsou HY, et al. (2011). Formulation optimization of transdermal meloxicam potassium-loaded mesomorphic phases containing ethanol, oleic acid and mixture surfactant using the statistical experimental design methodology. J Microencapsul 28:508–14
   PubMed Web of Science ®Google Scholar
• Inal O, Yapar EA. (2013). Effect of mechanical properties on the release of meloxicam from poloxamer gel bases. Indian J Pharm Sci 75:700–6
   PubMed Web of Science ®Google Scholar
• Jain D, Pathak K. (2010). Design, characterization, and evaluation of meloxicam gel prepared by suspension and solution polymerization using solubility parameter as the basis for development. AAPS PharmSciTech 11:133–42
   PubMed Web of Science ®Google Scholar
• Jain SK, Gupta Y, Jain A, et al. (2008). Elastic liposomes bearing meloxicam-beta-cyclodextrin for transdermal delivery. Curr Drug Deliv 5:207–14
   PubMedGoogle Scholar
• Jantharaprapap R, Stagni G. (2007). Effects of penetration enhancers on in vitro permeability of meloxicam gels. Int J Pharm 343:26–33
   PubMed Web of Science ®Google Scholar
• Khalil RM, Abd-Elbary A, Kassem MA, et al. (2014). Nanostructured lipid carriers (NLCs) versus solid lipid nanoparticles (SLNs) for topical delivery of meloxicam. Pharm Dev Technol 19:304–14
   PubMed Web of Science ®Google Scholar
• Khurana S, Bedi P, Jain N. (2013a). Preparation and evaluation of solid lipid nanoparticles based nanogel for dermal delivery of meloxicam. Chem Phys Lipids 175:65–72
   PubMed Web of Science ®Google Scholar
• Khurana S, Jain NK, Bedi PM. (2013b). Development and characterization of a novel controlled release drug delivery system based on nanostructured lipid carriers gel for meloxicam. Life Sci 93:763–72
   PubMed Web of Science ®Google Scholar
• Khurana S, Jain NK, Bedi PM. (2013c). Nanoemulsion based gel for transdermal delivery of meloxicam: physico-chemical, mechanistic investigation. Life Sci 92:383–92
   PubMed Web of Science ®Google Scholar
• Khurana S, Jain NK, Bedi PM. (2015). Nanostructured lipid carriers based nanogel for meloxicam delivery: mechanistic, in-vivo and stability evaluation. Drug Dev Ind Pharm 41:1368–75
   PubMed Web of Science ®Google Scholar
• Ki HM, Choi HK. (2007). The effect of meloxicam/ethanolamine salt formation on percutaneous absorption of meloxicam. Arch Pharm Res 30:215–21
   PubMed Web of Science ®Google Scholar
• Kim T, Kim Y, Seo S, et al. (2009). Anti-hyperalgesic effects of meloxicam hydrogel via phonophoresis in acute inflammation in rats; comparing systemic and topical application. Biomol Ther (Seoul) 17:305–10
   Web of Science ®Google Scholar
• Kumar M, Chauhan AK, Kumar S, et al. (2010). Design and evaluation of pectin based metrics for transdermal patches of meloxicam. JPRHC 2:244–7
   Google Scholar
• Lanes SF, Rodrigeuz LA, Hwangg E. (2000). Baseline risk of gastrointestinal disorders among new users of meloxicam, ibuprofen, diclofenac, naproxen and indomethacin. Pharmacoepidemiol Drug Saf 9:113–17
   PubMed Web of Science ®Google Scholar
• Luger P, Daneck K, Engel W, et al. (1996). Structure and physicochemical properties of meloxicam, a new NSAID. Eur J Pharm Sci 4:175–87
   Web of Science ®Google Scholar
• Mazzenga GC, Berner B. (1991). The transdermal delivery of zwitterionic drugs I: the solubility of zwitterion salts. J Control Release 16:77–88
   Web of Science ®Google Scholar
• Mezei M, Gulasekharam V. (1980). Liposomes-a selective drug delivery system for the topical route of administration I. Lotion dosage form. Life Sci 26:1473–7
   PubMed Web of Science ®Google Scholar
• Miller MA, Pisani E. (1999). The cost of unsafe injections. Bull World Health Organ 77:808–11
   PubMed Web of Science ®Google Scholar
• Mohammadi-Samani S, Yousefi G, Mohammadi F, et al. (2014). Meloxicam transdermal delivery: effect of eutectic point on the rate and extent of skin permeation. Iran J Basic Med Sci 17:112–18
   PubMed Web of Science ®Google Scholar
• Montejo C, Barcia E, Negro S, et al. (2010). Effective antiproliferative effect of meloxicam on prostate cancer cells: development of a new controlled release system. Int J Pharm 387:223–9
   PubMed Web of Science ®Google Scholar
• Muller RH, Mader K, Gohla S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 50:161–77
   PubMed Web of Science ®Google Scholar
• Ngawhirunpat T, Opanasopit P, Rojanarata T, et al. (2009). Development of meloxicam-loaded electrospun polyvinyl alcohol mats as a transdermal therapeutic agent. Pharm Dev Technol 14:70–9
   PubMed Web of Science ®Google Scholar
• Nief RA, Hussein AA. (2014). Preparation and evaluation of meloxicam microsponges as transdermal delivery system. Iraqi J Pharm Sci 23:62–74
   Google Scholar
• Pairet M, van Ryn J, Schierok H, et al. (1998). Differential inhibition of cyclooxygenases-1 and -2 by meloxicam and its 4'-isomer. Inflamm Res 47:270–6
   PubMed Web of Science ®Google Scholar
• Patel M, Joshi A, Hassanzadeth H, et al. (2011). Quantification of dermal and transdermal delivery of meloxicam gels in rabbits. Drug Dev Ind Pharm 37:613–17
   PubMed Web of Science ®Google Scholar
• Patel MM, Amin AF. (2011). Formulation and development of release modulated colon targeted system of meloxicam for potential application in the prophylaxis of colorectal cancer. Drug Deliv 18:281–93
   PubMed Web of Science ®Google Scholar
• Patoia L, Santucci L, Furno P, et al. (1996). A 4-week, double-blind, parallel-group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg, piroxicam 20 mg and placebo by means of faecal blood loss, endoscopy and symptom evaluation in healthy volunteers. Rheumatology (Oxford) 35:61–7
   Web of Science ®Google Scholar
• Persons AGSPoPMoPPiO (2009). Pharmacological management of persistent pain in older persons. J Am Geriatr Soc 57:1331--46
   PubMed Web of Science ®Google Scholar
• Prausnitz MR, Langer R. (2008). Transdermal drug delivery. Nat Biotechnol 26:1261–8
   PubMed Web of Science ®Google Scholar
• Prausnitz MR, Mitragotri S, Langer R. (2004). Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov 3:115–24
   PubMed Web of Science ®Google Scholar
• Rømsing J, Mysager S, Vilmann P, et al. (2001). Postoperative analgesia is not different after local vs systemic administration of meloxicam in patients undergoing inguinal hernia repair. Can J Anaesth 48:978–84
   PubMed Web of Science ®Google Scholar
• Rehman K, Zulfakar MH. (2014). Recent advances in gel technologies for topical and transdermal drug delivery. Drug Dev Ind Pharm 40:433–40
   PubMed Web of Science ®Google Scholar
• Ren-Jiunn W, Pao-Chu W, Huang Y-B, Yi-Hung T. (2008). The effects of iontophoresis and electroporation on transdermal delivery of meloxicam salts evaluated in vitro and in vivo. J Food Drug Anal 16:41–8
   Web of Science ®Google Scholar
• Ruiz Martinez MA, Lopez-Viota Gallardo J, de Benavides MM, et al. (2007). Rheological behavior of gels and meloxicam release. Int J Pharm 333:17–23
   PubMed Web of Science ®Google Scholar
• Saleem M, Bala S, Liyakat AA. (2010). Effect of different carriers on in vitro permeation of meloxicam through rat skin. Indian J Pharm Sci 72:710--18
   PubMed Web of Science ®Google Scholar
• Sareen R, Kumar S, Gupta GD. (2011). Meloxicam carbopol-based gels: characterization and evaluation. Curr Drug Deliv 8:407–15
   PubMed Web of Science ®Google Scholar
• Senna GE, Passalacqua G, Dama A, et al. (2003). Nimesulide and meloxicam are a safe alternative drugs for patients intolerant to nonsteroidal anti-inflammatory drugs. Eur Ann Allergy Clin Immunol 35:393–6
   PubMedGoogle Scholar
• Stei P, Kruss B, Wiegleb J, et al. (1996). Local tissue tolerability of meloxicam, a new NSAID: indications for parenteral, dermal and mucosal administration. Br J Rheumatol 35:44–50
   PubMedGoogle Scholar
• Tenjarla S. (1999). Microemulsions: an overview and pharmaceutical applications. Crit Rev Ther Drug Carrier Syst 16:461–521
   PubMed Web of Science ®Google Scholar
• Touitou E, Dayan N, Bergelson L, et al. (2000). Ethosomes – novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. J Control Release 65:403–18
   PubMed Web of Science ®Google Scholar
• Tsubouchi Y, Mukai S, Kawahito Y, et al. (1999). Meloxicam inhibits the growth of non-small cell lung cancer. Anticancer Res 20:2867–72
   Web of Science ®Google Scholar
• van den Bergh BA, Bouwstra JA, Junginger HE, et al. (1999). Elasticity of vesicles affects hairless mouse skin structure and permeability. J Control Release 62:367–79
   PubMed Web of Science ®Google Scholar
• Vintiloiu A, Leroux J-C. (2008). Organogels and their use in drug delivery – a review. J Control Release 125:179–92
   PubMed Web of Science ®Google Scholar
• Wang Y, Chen M, Li X, et al. (2008). A hybrid thermo-sensitive chitosan gel for sustained release of Meloxicam. J Biomater Sci Polym Ed 19:1239–47
   PubMed Web of Science ®Google Scholar
• Wiechers JW. (1989). The barrier function of the skin in relation to percutaneous absorption of drugs. Pharm Weekbl Sci 11:185–98
   PubMedGoogle Scholar
• Yener G, Uner M, Gonullu U, et al. (2010). Design of meloxicam and lornoxicam transdermal patches: preparation, physical characterization, ex vivo and in vivo studies. Chem Pharm Bull (Tokyo) 58:1466–73
   PubMed Web of Science ®Google Scholar
• Yuan Y, Chen X, Zhong D. (2007). Determination of meloxicam in human plasma by liquid chromatography-tandem mass spectrometry following transdermal administration. J Chromatogr B Analyt Technol Biomed Life Sci 852:650–4
   PubMed Web of Science ®Google Scholar
• Yuan Y, Chen XY, Li SM, et al. (2009). Pharmacokinetic studies of meloxicam following oral and transdermal administration in Beagle dogs. Acta Pharmacol Sin 30:1060–4
   PubMed Web of Science ®Google Scholar
• Yuan Y, Li SM, Mo FK, et al. (2006). Investigation of microemulsion system for transdermal delivery of meloxicam. Int J Pharm 321:117–23
   PubMed Web of Science ®Google Scholar
• Yue Y, LI S-m, YU L-m, et al. (2007). Physicochemical properties and evaluation of microemulsion systems for transdermal delivery of meloxicam. Chem Res Chinese U 23:81–6
   Web of Science ®Google Scholar
• Zhang JY, Fang L, Tan Z, et al. (2009). Influence of ion-pairing and chemical enhancers on the transdermal delivery of meloxicam. Drug Dev Ind Pharm 35:663–70
   PubMed Web of Science ®Google Scholar